Related Experiment Video
Updated: Jun 21, 2026
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
The future of small molecule inhibitors in lymphoma
1Department of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. gerecitj@mskcc.org
Abstract:
For the many patients with lymphoma that has relapsed after and/or has become refractory to existing treatments, the development of novel therapeutics is imperative. Investigation into intracellular processes that are dysregulated during lymphomagenesis has uncovered several new potential targets for anticancer agents. Although monoclonal antibodies and other immunotherapeutics have led to dramatic advances in the treatment of patients with lymphoma, the parallel development of small molecule inhibitors has been equally exciting. These agents, whose small size allows direct entry into tumor cells, can target distinct proteins or complexes, thereby disrupting molecular processes on which neoplastic cells depend for survival and growth. This review surveys the published literature on many of these new targeted molecules, focusing on some of the most promising agents for which phase 2 data currently exist. It also explores the potential for incorporating these agents into broader multidrug regimens.
Insights
Novel small molecule inhibitors offer new hope for lymphoma patients resistant to current therapies. These targeted agents disrupt cancer cell survival, showing promise in early clinical trials for improved treatment outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Lymphoma treatment faces challenges with relapsed or refractory disease.
- Intracellular dysregulation in lymphomagenesis presents new therapeutic targets.
- Advances in immunotherapeutics have improved lymphoma treatment.
Purpose of the Study:
- To review novel targeted small molecule inhibitors for lymphoma.
- To focus on agents with existing Phase 2 clinical data.
- To explore combination therapy potential.
Main Methods:
- Literature survey of targeted small molecule inhibitors.
- Analysis of agents targeting intracellular processes in lymphoma.
- Review of Phase 2 clinical trial data.
Main Results:
- Several promising small molecule inhibitors have been identified.
- These agents target critical molecular pathways in neoplastic cells.
- Phase 2 data indicate therapeutic potential for these novel agents.
Conclusions:
- Small molecule inhibitors are a vital addition to lymphoma treatment.
- Targeted therapies offer new strategies for refractory and relapsed lymphoma.
- Further research into combination regimens is warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:30Inhibitors of Viral Protein Synthesis